Lead Product(s): Brilacidin
Therapeutic Area: Dental and Oral Health
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Innovation Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 29, 2020
This renewed engagement is a continuation of Innovation Pharmaceuticalâ€™s business relationship with Locust Walk toward realizing the market potential of the Companyâ€™s pipeline.